U
Ursula Schmidt-Erfurth
Researcher at Medical University of Vienna
Publications - 703
Citations - 34745
Ursula Schmidt-Erfurth is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Macular degeneration & Optical coherence tomography. The author has an hindex of 82, co-authored 638 publications receiving 28143 citations. Previous affiliations of Ursula Schmidt-Erfurth include University of Vienna & Yahoo!.
Papers
More filters
Journal ArticleDOI
Intravitreal bevacizumab (Avastin®) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial
Franz Prager,Stephan Michels,Katharina Kriechbaum,Michael Georgopoulos,Marion Funk,Wolfgang Geitzenauer,Kaija Polak,Ursula Schmidt-Erfurth +7 more
TL;DR: Intravitreal therapy using bevacizumab appears to be a safe and effective treatment in patients with macular oedema secondary to retinal vein occlusion, however, the main limitations of this treatment modality are its short-term effectiveness and high recurrence rate.
Journal ArticleDOI
A Preliminary Study of Photodynamic Therapy Using Verteporfin for Choroidal Neovascularization in Pathologic Myopia, Ocular Histoplasmosis Syndrome, Angioid Streaks, and Idiopathic Causes
M. Sickenberg,Ursula Schmidt-Erfurth,Joan W. Miller,Constantin J. Pournaras,Leonidas Zografos,Bertrand Piguet,Guy Donati,H. Laqua,Irene Barbazetto,Evangelos S. Gragoudas,Anne Marie Lane,Reginald Birngruber,H. van den Bergh,Strong Ha,U. Manjuris,Todd Gray,Mario Fsadni,Neil M. Bressler +17 more
TL;DR: Treatment of CNV not related to AMD with verteporfin therapy achieves short-term cessation of fluorescein leakage from CNV in a small number of patients without loss of vision.
Journal ArticleDOI
Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab.
Marion Funk,Katharina Kriechbaum,Franz Prager,Thomas Benesch,Michael Georgopoulos,Gerhard J. Zlabinger,Ursula Schmidt-Erfurth +6 more
TL;DR: Intravitreal injections of bevacizumab resulted in a substantial decrease of VEGF under physiologic levels and remained low under the loading dose of three consecutive monthly retreatments.
Journal ArticleDOI
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.
Mark S. Blumenkranz,Neil M. Bressler,Susan B. Bressler,Guy Donati,Gary E. Fish,Laurie Haynes,Hilel Lewis,Joan W. Miller,Jordi Monés,Michael J. Potter,Constantin J. Pournaras,Reaves A,Philip J. Rosenfeld,Andrew P. Schachat,Ursula Schmidt-Erfurth,M. Sickenberg,Lawrence J. Singerman,Jason S. Slakter,H. Andrew Strong,Stéphane Vannier +19 more
TL;DR: To report vision and safety outcomes from an extension of a 2-year investigation evaluating verteporfin photodynamic therapy in patients with age-related macular degeneration with subfoveal choroidal neovascularization (CNV).
Journal ArticleDOI
Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study
Katharina Kriechbaum,Stephan Michels,Franz Prager,Michael Georgopoulos,Marion Funk,Wolfgang Geitzenauer,Ursula Schmidt-Erfurth +6 more
TL;DR: Intravitreal injections of bevacizumab appear to be a safe and effective therapy in the treatment of macular oedema secondary to retinal vein occlusion.